- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Gilbert, Arizona + 119 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 157
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- rHuPH20, Insulin Human Injection, Insulin Lispro Injection
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Interventions
- TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin Glargine, Insulin Aspart, Insulin Lispro
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Diabetes Mellitus
- Interventions
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
- Drug · Device
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Metabolic Integrity
- Interventions
- Humulin, Humalog, Novolog
- Procedure
- Lead sponsor
- Global Infusion and Aspiration Systems, LLC
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Batesville, Mississippi
- Conditions
- Type 2 Diabetes
- Interventions
- insulin lispro protamine suspension:insulin lispro rDNA origin low mix, insulin glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 79 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
- Drug · Other · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 39
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 35 more
- Conditions
- Gestational Diabetes Mellitus, Pregnancy, High Risk
- Interventions
- Metformin, Insulin
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 26
- States / cities
- Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more
- Conditions
- Hyperglycemia
- Interventions
- NPH insulin plus Complete Insulin Orders, Complete Insulin Orders
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Saint Louis Park, Minnesota
- Conditions
- Healthy
- Interventions
- Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SAR342434, Humalog, insulin glargine HOE901
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 51
- States / cities
- Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more
- Conditions
- Type 1 Diabetes
- Interventions
- Bi-homonal Bionic Pancreas, Usual care
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 933 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Fresno, California • La Mesa, California • Lancaster, California + 26 more
- Conditions
- Gestational Diabetes, Pregnancy Related
- Interventions
- Insulin
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Rochester, New York • Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 22
- States / cities
- Concord, California • Encino, California • Escondido, California + 18 more
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Insulin Lispro Protamine Suspension, Detemir
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 27
- States / cities
- Hueytown, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine, LY2189265, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 884 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 36
- States / cities
- Concord, California • La Mesa, California • Lancaster, California + 33 more
- Conditions
- Type 1 Diabetes
- Interventions
- Multiplex pharmacokinetic profiling, Continuous insulin monitoring
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Chula Vista, California